
Claims

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, and wherein the composition is to be administered to a subject at a dose of 1 to 6 mg/kg as said Compound I.




(I)

2. The use according to claim 1, wherein the composition is to be administered to a subject at a dose of 1 mg/kg, 3 mg/kg or 6 mg/kg as said Compound I.

3. The use according to claim 1 or 2, wherein a single dose of Compound I or a salt thereof is contained in a sealed container together with a pharmacologically acceptable carrier.

4. The use according to any one of claims 1 to 3, wherein 20 mg to 1000 mg of Compound I or a salt thereof is contained in a sealed container together with a pharmacologically acceptable carrier.

5. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, and wherein the composition is to be administered to a subject within 12 hours of the onset of cerebral infarction.



(I)

6. The use according to claim 5, wherein the composition is to be administered to a subject 3 to 12 hours after the onset of cerebral infarction, or preferably 4.5 to 12 hours after the onset of cerebral infarction.

7. The use according to claim 5 or 6, wherein the composition is to be administered to a subject at a dose of 1 to 6 mg/kg as said Compound I.

8. The use according to claim 7, wherein the composition is to be administered to a subject at a dose of 1 mg/kg, 3 mg/kg or 6 mg/kg as said Compound I.

9. The use according to any one of claims 1 to 8, wherein the composition is to be administered to a subject having a risk of causing hemorrhage, preferably the hemorrhage is intracranial or extracranial hemorrhage.

10. The use according to any one of claims 1 to 8, wherein the composition is to be administered to a subject with cerebral infarction having vascular occlusion including partial occlusion.

11. The use according to any one of claims 1 to 10, wherein the composition is to be administered intravenously.

12. The use according to any one of claims 1 to 11, wherein the composition is to be administered once daily, preferably in a single dose.

13. The use according to any one of claims 1 to 12, wherein the composition is to be administered as a bolus and subsequently, wherein the composition is to be administered continuously.


14. The use according to claim 13, wherein the composition is to be administered intravenously over 1 minute followed by infusion over 30 minutes.

15. The use according to any one of claims 1 to 14, wherein the composition is to be administered to a subject to whom administration of a thrombolytic agent or physical thrombectomy is difficult or impossible.

16. The use according to claim 15, wherein the thrombolytic agent is a tissue plasminogen activator.


17. The use according to any one of claims 1 to 16, wherein the cerebral infarction is atherothrombotic/embolic cerebral infarction, cardiogenic cerebral infarction or lacunar cerebral infarction.

18. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, wherein the composition is to recanalize occluded vessel in cerebral infarction.




(I)

19. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, wherein the composition is to be administered to a subject having a risk of causing hemorrhage.




(I)

20. Use of a pharmaceutical composition in the manufacture of a medicament for reducing risk of causing hemorrhage in cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof.



(I)

21. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, wherein the composition is to improve a life of independence after cerebral infarction.




(I)

22. The use according to claim 21, wherein an index of the improvement of a life of independence is outcome of mRS (modified Rankin Scale) of 0-1 on Day 90 after the composition is to be administered, or preferably an index of the improvement of a life of independence is outcome of mRS (modified Rankin Scale) of 0-2 on Day 90 after the composition is to be administered.


23. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I

having the structure of formula (I) or a salt thereof, wherein the composition has an action to dissolve a thrombus of a cerebral infarction patient.



(I)

24. Use of a pharmaceutical composition in the manufacture of a medicament for treating cerebral infarction, wherein the composition comprises Compound I having the structure of formula (I) or a salt thereof, wherein the composition has a low risk of a hemorrhagic side effect.



(I)

25. The use according to claim 24, wherein the hemorrhagic side effect is symptomatic intracranial hemorrhage.

26. The use according to any one of claims 1 to 25, comprising either or both of a basic additive and an amphipathic additive.

27. The use according to claim 26, wherein the basic additive is one or more selected from the group consisting of amino sugars, alkanolamines and trometamol salts, preferably, one or more selected from the group consisting of meglumine, triethanolamine and trometamol hydrochloride, and wherein the amphipathic additive is one or more selected from the group consisting of polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monolaurate, polyoxyethylene-polyoxypropylene glycol, polysorbate, polyethylene glycol, ursodesocy cholic acid, sorbitan fatty acid ester and sodium desoxycholate, preferably, one or more selected from the group consisting of polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil and polyoxyethylene sorbitan monolaurate.

28. The use according to any one of claims 1 to 27, wherein cerebral infarction is ischemic stroke.

29. The use according to claim 28, wherein the cerebral infarction is acute cerebral infarction or wherein the ischemic stroke is acute ischemic stroke.